Proto Labs and Oracle Options Trading Activity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RARE?
Source: NASDAQ.COM
- Proto Labs Options Volume: Proto Labs Inc (Ticker: PRLB) has seen an options trading volume of 1,016 contracts today, equating to approximately 101,600 shares, which represents a notable 58.4% of its average daily trading volume of 173,865 shares over the past month.
- High Call Option Activity: Within PRLB, the $60 strike call option has been particularly active, with 1,010 contracts traded today, representing about 101,000 underlying shares, indicating market expectations for potential upward movement in the stock.
- Oracle Options Trading Overview: Concurrently, Oracle Corp (Ticker: ORCL) has recorded an options trading volume of 167,812 contracts today, translating to approximately 16.8 million shares, which is about 55.9% of its average daily trading volume of 30 million shares over the past month, reflecting significant market interest.
- Active Put Option Trading: For ORCL, the $135 strike put option has seen a trading volume of 11,501 contracts, representing around 1.2 million shares, suggesting investor concerns regarding potential declines in the stock's price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.000
Low
35.00
Averages
61.65
High
120.00
Current: 20.000
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical faces a class action lawsuit for false statements made between August 3, 2023, and December 26, 2025, with investors needing to apply as lead plaintiff by April 6, 2026, highlighting significant legal risks and potential financial losses for the company.
- Stock Price Volatility: Following the announcement on July 9, 2025, that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%, and after the December 29, 2025, announcement of further study failures, the stock fell another 42%, reflecting extreme market pessimism regarding the company's future.
- Details of Legal Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the risks associated with Osteogenesis Imperfecta, failing to disclose critical information that severely undermined investor confidence and could impact the company's ability to raise funds.
- Role of Robbins Geller: Robbins Geller, a leading class action law firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud cases, which may significantly influence the outcome of the Ultragenyx lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Ultragenyx Pharmaceutical and its executives, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta, leading investors to have a distorted view of the company's prospects.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, indicating the importance of investor initiative in legal proceedings and potentially influencing future compensation outcomes.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and protecting investor rights.
See More
Faruqi & Faruqi Encourages Ultragenyx Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, specifically targeting investors who purchased or acquired securities between August 3, 2023, and December 26, 2025, reminding them of their legal rights.
- Investor Contact Information: Investors who have suffered losses are encouraged to contact Faruq & Faruqi's Securities Litigation Partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026, urging investors to act before this date to protect their rights.
- Potential Claims Investigation: As a leading national securities law firm, Faruq & Faruqi is actively investigating potential claims against Ultragenyx, demonstrating a commitment to investor rights that may impact the company's reputation and stock price.
See More
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), concealing critical negative information that led to inflated stock purchases and subsequent investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, highlighting its expertise and successful track record, which investors should consider when selecting legal counsel.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call their toll-free number for more information; although a class has not yet been certified, investors may choose to retain or change counsel to safeguard their interests.
See More
Ultragenyx Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant financial repercussions for investors.
- Impact of Clinical Trial Failures: On December 26, 2025, Ultragenyx announced that its Phase 3 studies for setrusumab (UX143) did not demonstrate a statistically significant reduction in fracture rates, resulting in a dramatic 42% drop in share price from $34.19 to $19.72 within three days.
- Cost Reduction Strategy: In light of the disappointing trial results, Ultragenyx stated it would evaluate its operational plans and promptly implement significant expense reductions to mitigate the financial impact of the stock price decline.
See More
Ultragenyx Pharmaceutical Class Action Notice Issued
- Class Action Deadline: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reminds stock purchasers from August 3, 2023, to December 26, 2025, that the lead plaintiff deadline is April 6, 2026, and failure to act may result in loss of rights to participate.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in Phase III studies, leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, emphasizing the importance of selecting experienced legal counsel for potential claimants.
- Investor Action Steps: Investors can join the class action by visiting the Rosen Law Firm's website or calling the toll-free number for more information, and while the class has not yet been certified, they can choose to retain or change their legal representation.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical faces a class action lawsuit for false statements made between August 3, 2023, and December 26, 2025, with investors needing to apply as lead plaintiff by April 6, 2026, highlighting significant legal risks and potential financial losses for the company.
- Stock Price Volatility: Following the announcement on July 9, 2025, that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%, and after the December 29, 2025, announcement of further study failures, the stock fell another 42%, reflecting extreme market pessimism regarding the company's future.
- Details of Legal Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the risks associated with Osteogenesis Imperfecta, failing to disclose critical information that severely undermined investor confidence and could impact the company's ability to raise funds.
- Role of Robbins Geller: Robbins Geller, a leading class action law firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud cases, which may significantly influence the outcome of the Ultragenyx lawsuit.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Ultragenyx Pharmaceutical and its executives, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta, leading investors to have a distorted view of the company's prospects.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, indicating the importance of investor initiative in legal proceedings and potentially influencing future compensation outcomes.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and protecting investor rights.
See More
Faruqi & Faruqi Encourages Ultragenyx Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, specifically targeting investors who purchased or acquired securities between August 3, 2023, and December 26, 2025, reminding them of their legal rights.
- Investor Contact Information: Investors who have suffered losses are encouraged to contact Faruq & Faruqi's Securities Litigation Partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026, urging investors to act before this date to protect their rights.
- Potential Claims Investigation: As a leading national securities law firm, Faruq & Faruqi is actively investigating potential claims against Ultragenyx, demonstrating a commitment to investor rights that may impact the company's reputation and stock price.
See More
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), concealing critical negative information that led to inflated stock purchases and subsequent investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, highlighting its expertise and successful track record, which investors should consider when selecting legal counsel.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call their toll-free number for more information; although a class has not yet been certified, investors may choose to retain or change counsel to safeguard their interests.
See More
Ultragenyx Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant financial repercussions for investors.
- Impact of Clinical Trial Failures: On December 26, 2025, Ultragenyx announced that its Phase 3 studies for setrusumab (UX143) did not demonstrate a statistically significant reduction in fracture rates, resulting in a dramatic 42% drop in share price from $34.19 to $19.72 within three days.
- Cost Reduction Strategy: In light of the disappointing trial results, Ultragenyx stated it would evaluate its operational plans and promptly implement significant expense reductions to mitigate the financial impact of the stock price decline.
See More
Ultragenyx Pharmaceutical Class Action Notice Issued
- Class Action Deadline: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reminds stock purchasers from August 3, 2023, to December 26, 2025, that the lead plaintiff deadline is April 6, 2026, and failure to act may result in loss of rights to participate.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in Phase III studies, leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, emphasizing the importance of selecting experienced legal counsel for potential claimants.
- Investor Action Steps: Investors can join the class action by visiting the Rosen Law Firm's website or calling the toll-free number for more information, and while the class has not yet been certified, they can choose to retain or change their legal representation.
See More
